Figure 4From: Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterationsFibroblast growth factor receptor (FGFR)4 deficiency reduces mitoses in breast tumor foci. The expression of Ki67 were assessed by immunohistochemical analyses of tissue sections from wild-type (WT) (A), FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) (B) and MMTV-TGFα transgenic (Tg) mice (C) (n = 12 for each group) at 6 months as indicated, and quantified by counting the positive dots in the populations of tumor cells in different random fields under the light microscope (D). Data are expressed as percentage and means ± SD; *P <0.05.Back to article page